| Literature DB >> 25975173 |
Susanna Kemppainen1, Päivi Lindholm2, Emilia Galli2, Hanna-Maija Lahtinen1, Henna Koivisto1, Elina Hämäläinen1, Mart Saarma2, Heikki Tanila3.
Abstract
Cerebral dopamine neurotrophic factor (CDNF) protects and repairs dopamine neurons in animal models of Parkinson's disease, which motivated us to investigate its therapeutic effect in an animal model of Alzheimer's disease (AD). We employed an established APP/PS1 mouse model of AD and gave intrahippocampal injections of CDNF protein or CDNF transgene in an AAV2 viral vector to 1-year-old animals. We performed a behavioral test battery 2 weeks after the injections and collected tissue samples after the 3-week test period. Intrahippocampal CDNF-therapy improved long-term memory in both APP/PS1 mice and wild-type controls, but did not affect spontaneous exploration, object neophobia or early stages of spatial learning. The memory improvement was not associated with decreased brain amyloid load or enhanced hippocampal neurogenesis. Intracranial CDNF treatment has beneficial effects on long-term memory and is well tolerated. The CDNF molecular mechanisms of action on memory await further studies.Entities:
Keywords: Amyloid; Gene therapy; Memory; Neurotrophic factor; Transgenic
Mesh:
Substances:
Year: 2015 PMID: 25975173 DOI: 10.1016/j.bbr.2015.05.002
Source DB: PubMed Journal: Behav Brain Res ISSN: 0166-4328 Impact factor: 3.332